The Oncology Institute, Inc. (TOI)
- Previous Close
2.7100 - Open
2.8900 - Bid 2.8400 x 1000
- Ask 2.9700 x 100
- Day's Range
2.6320 - 2.9450 - 52 Week Range
0.1250 - 2.9600 - Volume
1,225,625 - Avg. Volume
850,281 - Market Cap (intraday)
252.748M - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7500 - Earnings Date May 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services. The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies. It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
theoncologyinstitute.com825
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: TOI
View MorePerformance Overview: TOI
Trailing total returns as of 4/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TOI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TOI
View MoreValuation Measures
Market Cap
237.83M
Enterprise Value
311.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.52
Price/Book (mrq)
66.27
Enterprise Value/Revenue
0.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.44%
Return on Assets (ttm)
-19.67%
Return on Equity (ttm)
-213.36%
Revenue (ttm)
393.41M
Net Income Avi to Common (ttm)
-53.01M
Diluted EPS (ttm)
-0.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
49.67M
Total Debt/Equity (mrq)
3,434.19%
Levered Free Cash Flow (ttm)
-7.46M